Evidence Table 94. KQ3—Continuous Alanine transaminase (ALT)

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD**  **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lee 200836  Parallel | At high risk for CHD | Warfarin | 3.5 | Ginseng | 12 | NR  Unit: U/L | Mean: 22.09  SD: 7.19 | Mean:0.18 | NR | There were no statistically significant differences between the two groups. | N/A |
| No treatment | 13 | Mean:23.15  SD: 5.61 | Mean:1.8 |
| Mabuchi 200739  Parallel | Unclear | Atorvastatin | 10 | CoQ10 | 24 | NR  Unit: IU/L | Mean: 31.6  SD: 26.1 | Mean:18.4  P: 0.0219 | NR | There were no significant differences between the two groups. | Medium |
| Placebo | 25 | Mean:32.6  SD: 14.9 | Mean:21.6  P:0.0147 |
| Davidson 200714  Parallel | Unclear | Simvastatin | 40 | Omega 3 | 122 | NR  Unit: U/L | NR | Mean:5.7 | Mean:6.4  P: <0.001 | N/A | Medium |
| Placebo | 132 | NR | Mean: -0.7 |
| Nordøy 200054  Parallel | Mixed:  Low and/or mod to high risk | Simvastatin | 20 | Omega 3 |  | laboratory tests perfomed for liver function  Unit: NR | NR | NR | NR | No significant changes were observed in serum ALT | Medium |
| Placebo |  | NR | NR |

| Evidence Table 94. KQ3—Continuous Alanine transaminase (ALT) (continued) | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **CVD**  **Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| Napoli  199852  Parallel | Unclear | Pravastatin | 20-40 | Vitamin E |  | alanine aminotransferase  Unit: NR | NR | NR | NR | No differences in routine laboratory tests or adverse events were registered during the study. In particular, there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups. | Medium |
| No treatment |  | NR | NR |
| Budoff 200410  Parallel | At high risk for CHD | Satins + aspirin | 10-40 | Garlic | 9 | Measured after 12 hr fast  Unit: mg/dl | NR | Mean:0.11  SD:7.25 | P:0.5876 | N/A | Medium |
| Placebo | 10 | NR | Mean: -2.6  SD:13 |
| Lui 200337  Parallel | Unclear | Simvastatin | 10 | Omega3 | 19 | Narratively reported for post treatment  Unit: NR | NR: | NR | NR | N/A | Medium |
|  | Control | 18 | NR | NR |
| Wolf 200868  Crossover | Mixed:  Low and/or Moderate | ASA | 500 | Gingko biloba |  | NR  Unit: NR | NR | NR | NR | Study states that: Laboratory findings in all subjects were un-remarkable and did not indicate any differences between the treatment groups. | Medium |
|  |  | NR | NR |